{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:00:53Z","timestamp":1761897653066,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008467","name":"ACRO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008467","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.prro.2021.11.010","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T02:14:09Z","timestamp":1639188849000},"page":"e135-e143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Is Radiation Therapy Cost-Effective in the Positron Emission Tomography\/Computed Tomography Era for Early-Stage Favorable Hodgkin Lymphoma With Alternative Payment Models?"],"prefix":"10.1016","volume":"12","author":[{"given":"Hayeon","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Richman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parvez M.","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushil","family":"Beriwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Vargo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2021.11.010_bib0001","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin's lymphoma: Final results of the randomized EORTC\/LYSA\/FIL H10 Trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2021.11.010_bib0002","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2021.11.010_bib0003","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin's lymphoma: Final results of the international, randomized phase III trial by the German Hodgkin's study group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2021.11.010_bib0004","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1080\/10428190701559140","article-title":"Randomized comparison of consolidative radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans","volume":"48","author":"Picardi","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.prro.2021.11.010_bib0005","first-page":"1","article-title":"Consolidative radiotherapy following positron emission tomography complete response in early-stage Hodgkin lymphoma: A meta-analysis","volume":"12","author":"Shaikh","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.prro.2021.11.010_bib0006","doi-asserted-by":"crossref","first-page":"755","DOI":"10.6004\/jnccn.2020.0026","article-title":"Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Hoppe","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.prro.2021.11.010_bib0007","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/j.prro.2020.04.011","article-title":"Radiation oncology APM: An introduction and primer for the proposed rule for practices and providers","volume":"11","author":"Li","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2021.11.010_bib0008","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.ijrobp.2019.12.012","article-title":"Impact of patient stage and disease characteristics on the proposed radiation oncology alternative payment model (RO-APM)","volume":"106","author":"Waddle","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2021.11.010_bib0009","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.ijrobp.2020.01.024","article-title":"The ASTRO perspective on \u201cImpact of patient stage and disease characteristics on the proposed radiation oncology alternative payment model (RO-APM) at a large academic cancer center","volume":"106","author":"Mohideen","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2021.11.010_bib0010","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/hon.104_2630","article-title":"Outcome and treatment of relapsing early PET negative patients included in the EORTC\/LYSA\/FIL H10 trial on stage I\/II Hodgkin lymphoma","volume":"37S2","author":"Gac","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.prro.2021.11.010_bib0011","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2021.11.010_bib0012","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2021.11.010_bib0013","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/hed.25142","article-title":"Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer","volume":"40","author":"Kim","year":"2018","journal-title":"Head Neck"},{"key":"10.1016\/j.prro.2021.11.010_bib0014","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1200\/JCO.18.00122","article-title":"Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III and IV Hodgkin lymphoma","volume":"36","author":"Huntington","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2021.11.010_bib0015","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.15255","article-title":"Early-stage Hodgkin lymphoma in the modern era: Simulation modelling to delineate long-term patient outcomes","volume":"182","author":"Parsons","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.prro.2021.11.010_bib0016","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.2017.35.15_suppl.e19011","article-title":"A trial-based EUROQOL EQ-5D health utility analysis in patients with classical Hodgkin's lymphoma","volume":"35","author":"Wu","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2021.11.010_bib0017","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S2352-3026(19)30218-2","article-title":"Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: A modelling study","volume":"7","author":"Vijenthira","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.prro.2021.11.010_bib0018","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness: The curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2021.11.010_bib0019","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MLR.0b013e31815c31a7","article-title":"What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?","volume":"46","author":"Braithwaite","year":"2008","journal-title":"Med Care"},{"key":"10.1016\/j.prro.2021.11.010_bib0020","unstructured":"Centers for Medicare & Medicaid Services. Home page. Available at: www.cms.gov\/. Accessed August 15, 2020."},{"key":"10.1016\/j.prro.2021.11.010_bib0021","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/bmt.2012.133","article-title":"Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: A study using a large national private claims database","volume":"48","author":"Majhail","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.prro.2021.11.010_bib0022","unstructured":"Centers for Medicare & Medicaid Services. 2019 ASP drug pricing files. Available at: https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Part-B-Drugs\/McrPartBDrugAvgSalesPrice\/2019ASPFiles. Accessed August 24, 2020."},{"key":"10.1016\/j.prro.2021.11.010_bib0023","unstructured":"Agency for Healthcare Research and Quality. Healthcare cost and utility project. Available at: http:\/\/hcupnet.ahrq.gov. Accessed August 15, 2020."},{"key":"10.1016\/j.prro.2021.11.010_bib0024","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.radonc.2015.10.022","article-title":"Association of intensity modulated radiation therapy on overall survival for patients with Hodgkin lymphoma","volume":"118","author":"Parikh","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2021.11.010_bib0025","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ijrobp.2014.01.041","article-title":"Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma","volume":"89","author":"Filippi","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2021.11.010_bib0026","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20150409","article-title":"Evolution of radiation techniques in the treatment of mediastinal lymphoma: from 3D conformal radiotherapy (3DCRT) to intensity-modulated RT (IMRT) using helical tomotherapy (HT): A single-centre experience and review of the literature","volume":"89","author":"Besson","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1016\/j.prro.2021.11.010_bib0027","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ijrobp.2015.06.039","article-title":"Early-stage classical Hodgkin lymphoma: The impact of radiation therapy and its impact on overall survival","volume":"93","author":"Parikh","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2021.11.010_bib0028","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1002\/cncr.29491","article-title":"Beriwal S. What is the optimal management of early-stage low-grade follicular lymphoma in the modern era?","volume":"121","author":"Vargo","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.prro.2021.11.010_bib0029","doi-asserted-by":"crossref","first-page":"S6619","DOI":"10.1200\/JCO.2017.35.15_suppl.6619","article-title":"Cost-effectiveness analysis of first-line treatments for early-stage, low-grade follicular lymphoma","volume":"35","author":"Yang","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2021.11.010_bib0030","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1002\/cncr.29518","article-title":"Disparities in survival by insurance status in patients with Hodgkin lymphoma","volume":"121","author":"Parikh","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.prro.2021.11.010_bib0031","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1200\/JCO.2015.61.7654","article-title":"Treatment selection and survival outcomes in early-stage diffuse large B-cell lymphoma: Do we still need consolidative radiotherapy?","volume":"33","author":"Vargo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2021.11.010_bib0032","unstructured":"Connors JM, Yahalom J. Is there still a need for radiation therapy in Hodgkin lymphoma? Available at https:\/\/www.ashclinicalnews.org\/spotlight\/is-there-still-a-need-for-radiation-therapy-in-hodgkin-lymphoma\/. Accessed August 18, 2020."},{"key":"10.1016\/j.prro.2021.11.010_bib0033","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2147\/CEOR.S178649","article-title":"Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure","volume":"10","author":"Bonadefe","year":"2018","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.prro.2021.11.010_bib0034","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/13696998.2018.1542599","article-title":"Cost-effectiveness analysis of brentuximab vedotin plus chemotherapy as frontline treatment of stage III and IV classical Hodgkin lymphoma","volume":"22","author":"Delea","year":"2019","journal-title":"J Med Econ"},{"key":"10.1016\/j.prro.2021.11.010_bib0035","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1200\/JCO.2008.19.9174","article-title":"Breast cancer risk in female survivors of Hodgkin's lymphoma: Lower risk after smaller radiation volumes","volume":"27","author":"De Bruin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2021.11.010_bib0036","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin's lymphoma: Field and dose guidelines from the international radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2021.11.010_bib0037","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.prro.2019.05.009","article-title":"Comparison of techniques for involved-site radiation therapy in patients with lower mediastinal lymphoma","volume":"9","author":"Everett","year":"2019","journal-title":"Prac Radiat Oncol"},{"key":"10.1016\/j.prro.2021.11.010_bib0038","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","article-title":"Proton therapy for adults with mediastinal lymphomas: The International Lymphoma Radiation Oncology Group guidelines","volume":"132","author":"Dabaja","year":"2018","journal-title":"Blood"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850021003386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850021003386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:23:52Z","timestamp":1761819832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850021003386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1879850021003386"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2021.11.010","relation":{},"ISSN":["1879-8500"],"issn-type":[{"type":"print","value":"1879-8500"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is Radiation Therapy Cost-Effective in the Positron Emission Tomography\/Computed Tomography Era for Early-Stage Favorable Hodgkin Lymphoma With Alternative Payment Models?","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2021.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}